Dr Jean-Michel Cosséry appointed as Chairman

RNS Number : 4842O

Scancell Holdings Plc

01 February 2023

 

1 February 2023

Scancell Holdings Plc

("Scancell" or the "Company")

Directorate Change

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

Jean-Michel brings 25 years of experience in the international pharmaceutical and biotech industries

both in an executive and non-executive capacity

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer and infectious disease, today announces the appointment of Dr Jean-Michel Cosséry, as Non-Executive Chairman of the Board of Directors with immediate effect. As previously announced, Dr John Chiplin who has served as Chairman since 2016, will step down following Jean-Michel's appointment . Jean-Michel will seek to drive Scancell's strategy for clinical progress and commercial development of its novel immunotherapy vaccine and antibody platforms.

Jean-Michel brings to Scancell over 25 years of experience in the pharmaceutical and biotechnology industries and a sustained global track record of success in commercial operations as well as in capital raising, US and European public offerings, business development and M&A. Jean-Michel was Vice President for North America Oncology at Eli Lilly, with responsibility for commercialisation of the company's oncology portfolio . Preceding this US-based position, he was Vice President and Managing Director of the Eli Lilly's European Northern Hub, where he was Chair of the Eli Lilly UK Board and a member of Lilly European Executive Committee. Prior to this Jean-Michel served as VP and Chief Marketing Officer at GE Healthcare's Global Headquarters.

Following his retirement from Eli Lilly in 2018, Jean-Michel has served on the board of Kymab until their acquisition by Sanofi. He was also a member of the Immunocore board prior to the company's Nasdaq listing. Jean-Michel currently serves on the boards of Malin PLC, Exact Therapeutics AS, Eracal Therapeutics and Sophia Genetics SA. He has also been Chair of The American Pharmaceutical Group in the UK, as well as a board member of the Association of British Pharmaceutical Industry. Jean-Michel holds an MBA from the Rotterdam School of Management (Erasmus University), The Netherlands, as well as a PharmD and a PhD in Nuclear Chemistry and Neurobiology from University Paris, France.

Dr John Chiplin, former Chairman of the Board of Scancell, commented: 

"The last 7 years have been transformative for Scancell, I am leaving the Company with strong management and exciting prospects ahead. I would like to welcome Dr Jean-Michel Cosséry to Scancell, his extensive experience and accomplishments speak volumes and his expertise in oncology and corporate management will be invaluable as Scancell drive its immunotherapy products through the clinic, with the aim to provide new treatment options for patients with debilitating cancers."

Dr Jean-Michel Cosséry Chairman of the Board of Scancell, said:

"I am delighted to be joining the Scancell team at this pivotal time in the Company's evolution and to build on the rich history it has in developing four innovate platforms. I am excited about the clinical trials in progress and the life changing improvement these important novel cancer therapies can bring to patients, while enhancing shareholder value. I look forward to working with the Board and the Senior Management Team as we seek to advance Scancell's strategy."

Prof Lindy Durrant, Chief Executive Officer, Scancell, added:

"I speak on the behalf of all of Scancell that we are excited to welcome Jean-Michel and to capitalise on his experience as we continue on our journey to deliver the next stage of growth. I am deeply indebted to John Chiplin for his hard work, support and boundless enthusiasm over the last 7 years which has allowed us to build the Company into the strong business it is today."

Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Jean-Michel Yves Sylvain Cosséry, aged 63:

Current Directorships	Previous Directorships (last 5 years)
Malin Corporation Plc	Diurnal Group Limited
Malin Life Sciences Holdings Ltd EXACT Therapeutics AS	Kymab Group Limited Lilly USA LLC
EraCal Therapeutics AG	Immunocore Limited
SOPHiA GENETICS SA SCI Elyna

Dr Cossery does not have an interest in any ordinary shares of Scancell.

The Company confirms that there is no further information to be disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

For further information, please contact:
Scancell Holdings plc	[phone]
Dr Jean-Michel Cosséry, Non-Executive Chairman	[phone]
Professor Lindy Durrant, CEO
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)	[phone]
Nicholas Moore/ Samira Essebiyea/William Palmer-Brown (Healthcare Investment Banking)
Nick Adams/Nick Harland (Corporate Broking)
Panmure Gordon (UK) Limited (Joint Broker)	[phone]
Freddy Crossley/Emma Earl (Corporate Finance)
Rupert Dearden (Corporate Broking)
FTI Consulting	[phone]
Simon Conway/Rob Winder/Alex Davis

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope^® and ImmunoBody^® for vaccines and GlyMab^® and AvidiMab^® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope^® and ImmunoBody^®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab^®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab^®).

For further information about Scancell, please visit: https://www.scancell.co.uk/

 

END

 

 

BOAKZGFMNMFGFZM